Baudax Bio (BXRXV) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock BXRXV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Malvern-Based Baudax Bio Once Again Seeking to Extend Its Reorganization Plan DeadlineFebruary 27, 2025 | msn.comBaudax Bio of Malvern asks for 5th extension on reorganization plan deadlineFebruary 23, 2025 | bizjournals.comBaudax Bio Inc Ordinary Shares (OTC:BXRX) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comBaudax Bio Inc (BXRXQ)April 24, 2024 | investing.comBaudax Bio Inc Ordinary Shares BXRXQMarch 20, 2024 | morningstar.comMBaudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with InhibitorsSeptember 28, 2023 | stockhouse.comNoble Financial Remains a Hold on Baudax Bio (BXRX)August 23, 2023 | markets.businessinsider.comWhat's Happening With Baudax Bio Shares TodayJune 30, 2023 | msn.comBaudax Bio Soars on Snapping Up Cell Therapy Developer TeraImmuneJune 30, 2023 | msn.comBaudax Bio Acquires TeraImmune, Inc.June 30, 2023 | finance.yahoo.comBaudax Bio Touts Additional Positive Data From Nerve Blocker In Surgery PatientsJune 7, 2023 | benzinga.comBaudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000June 7, 2023 | technews.tmcnet.comBaudax Bio Announces Date of Reconvened Annual MeetingJune 6, 2023 | finance.yahoo.comBaudax Bio, Inc.: Baudax Bio Announces Pricing of $4 Million Public OfferingApril 27, 2023 | finanznachrichten.deBaudax Bio stock dips on pricing $4M stock offering at $1.15/shareApril 27, 2023 | msn.comBaudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000April 25, 2023 | finance.yahoo.comBaudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000March 27, 2023 | finance.yahoo.comWhy Baudax Bio Shares Trading Higher TodayJanuary 24, 2023 | finance.yahoo.comBaudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000January 24, 2023 | finance.yahoo.comBXRX Baudax Bio, Inc.January 14, 2023 | seekingalpha.comBaudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing SurgeryDecember 8, 2022 | finance.yahoo.comBaudax Bio Announces Closing of $5 Million Public OfferingDecember 6, 2022 | nz.finance.yahoo.comBaudax Bio, Inc.: Baudax Bio Announces Pricing of $5 Million Public OfferingDecember 3, 2022 | finanznachrichten.deBaudax Bio Announces Pricing of $5 Million Public OfferingDecember 2, 2022 | nz.finance.yahoo.comBaudax Bio Announces 1-for-40 Reverse Stock SplitNovember 30, 2022 | yahoo.comBaudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue EstimatesNovember 8, 2022 | msn.comBaudax Bio Announces Closing of $6.2 Million Public OfferingSeptember 1, 2022 | benzinga.comHow Is The Market Feeling About Baudax Bio?September 1, 2022 | msn.comBaudax Bio Shares Tumble Premarket After Public Offering >BXRXAugust 30, 2022 | marketwatch.comShort Volatility Alert: Baudax Bio, Inc.August 27, 2022 | uk.investing.comBaudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe painAugust 22, 2022 | finance.yahoo.comBaudax Bio, Inc. (BXRX) Reports Q2 Loss, Misses Revenue EstimatesAugust 11, 2022 | finance.yahoo.comBaudax Bio Reports Second Quarter 2022 Financial Results and Business HighlightsAugust 11, 2022 | finance.yahoo.comBaudax Bio, Inc. (BXRX)August 7, 2022 | finance.yahoo.comBaudax Bio plunges on launching $2M registered direct offering priced at-the-marketMay 18, 2022 | seekingalpha.comBaudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 17, 2022 | stockhouse.comBaudax Bio Reports First Quarter 2022 Financial Results and Business HighlightsMay 4, 2022 | apnews.comABaudax Bio Q1 2022 Earnings PreviewMay 4, 2022 | seekingalpha.comWhat Makes Baudax Bio, Inc. (BXRX) a New Strong Buy StockApril 11, 2022 | nasdaq.comBaudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following SurgeryMarch 8, 2022 | nz.finance.yahoo.comBaudax Bio regains compliance with Nasdaq's listing rulesMarch 7, 2022 | seekingalpha.comBaudax Bio wins new U.S. patent for pain therapyMarch 2, 2022 | seekingalpha.comBaudax Bio Shares Tumble Premarket on Public Offering >BXRXFebruary 25, 2022 | marketwatch.comBaudax Bio Announces Pricing of $10.0 Million Public OfferingFebruary 24, 2022 | yahoo.comPre-market Movers: STRR, BXRX, CALA, VALN, TKLF…January 20, 2022 | nasdaq.comBaudax Bio Inc Shares Close the Day 21.9% Lower - Daily WrapDecember 29, 2021 | nasdaq.comBaudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000November 11, 2021 | finance.yahoo.comBaudax Bio is about to announce earnings — here's what Wall Street expectsNovember 6, 2021 | markets.businessinsider.comBaudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitSeptember 16, 2021 | morningstar.comMDo Options Traders Know Something About Baudax Bio (BXRX) Stock We Don't?August 25, 2021 | nasdaq.com Get Baudax Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BXRXV and its competitors with MarketBeat's FREE daily newsletter. Email Address BXRXV Media Mentions By Week BXRXV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BXRXV News Sentiment▼0.000.59▲Average Medical News Sentiment BXRXV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BXRXV Articles This Week▼00▲BXRXV Articles Average Week Get Baudax Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BXRXV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 60 Degrees Pharmaceuticals News Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News BerGenBio ASA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BXRXV) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baudax Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
